By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



One Newton Executive Park
Suite 202
Newton  Massachusetts  02462  U.S.A.
Phone: 617-916-1207 Fax: 617-916-1871


Alcresta is developing and commercializing innovative, point-of-care, enzyme-based nutritional products designed to improve proper nutrition and support disease management. Alcresta’s research-based approach is innovative, proprietary and driven by the unmet nutritional needs of those people with compromised health. Alcresta’s core capabilities include expertise in adult and pediatric nutrition, as well as protein manufacturing expertise and regulatory experience that support the development and commercialization of its programs. The company’s platform is supported by the Alcresta team’s proven success in developing protein therapeutics.

The demand for high-value nutritional products is increasing, driving the growth of a $36 billion global market. Leveraging its existing proprietary platform of point-of-care nutritional products, Alcresta has developed a lead program designed to improve the digestion and absorption of fats, in particular long-chain polyunsaturated fatty acids (including omega-3 and omega-6), and improve caloric intake. The importance of LCPUFAs is well documented across the full spectrum of patient care from premature infants to aging adults and individuals battling acute conditions or chronic diseases.

Alcresta was founded in 2011 with $10 million in Series A venture capital financing led by top-tier venture investors Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures. In July 2013, the company secured an additional $10 million in Series B financing.

Based in Newton, Mass., Alcresta was co-founded by Alexey Margolin, Ph.D., and Robert Gallotto, industry leaders with proven and unique experience in protein therapeutic design and the development of nutritional products. Alcresta is leveraging its leadership team’s combined operational expertise in manufacturing, formulation and non-systemic protein delivery.

Key Statistics

Ownership: Private

Web Site: Alcresta
Employees: n/a


Start Up

Company News
Alcresta Announces Positive Results, Relizorb Increased Fat Absorption In Both Adult And Pediatric Patients With Cystic Fibrosis Receiving Enteral Nutrition 7/31/2017 11:42:31 AM
Alcresta Snags FDA 510(K) Clearance for Use Of Relizorb in Kids 7/20/2017 7:23:34 AM
Alcresta' RELiZORB Increases Fat Absorption In Adult And Pediatric Patients With Cystic Fibrosis Receiving Enteral Nutrition 10/31/2016 7:02:32 AM
Bridgemedica And Alcresta Honored As Gold Winners In The 2016 Medical Design Excellence Award (MDEA) 8/1/2016 11:11:42 AM
Alcresta Release: RELiZORB Recognized For Medical Design Excellence 7/28/2016 10:43:47 AM
Alcresta Launches RELiZORB In The U.S. 6/7/2016 11:19:42 AM
Alcresta To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/6/2016 12:14:07 PM
Alcresta Receives FDA Clearance For RELiZORB 12/2/2015 9:00:33 AM
Alcresta Appoints Russell Clayton, D.O., Chief Medical Officer 7/22/2015 11:00:16 AM
Alcresta Announces Agreement With Cystic Fibrosis Foundation To Develop Point-Of-Care Nutritional Products 9/26/2014 11:01:23 AM